Authored by Open Medicine, published on 2026-04-09 23:24:58.0
First-line treatment for advanced urothelial carcinoma now prioritizes enfortumab vedotin plus pembrolizumab, with alternatives including platinum-based chemotherapy followed by avelumab maintenance or chemo-immunotherapy combinations. Subsequent therapy is guided by prior exposure and biomarkers, incorporating options such as erdafitinib for FGFR-altered disease, HER2-targeted therapy, immunotherapy, or EV if not previously used.
Advanced bladder cancer
EV + Pembrolizumab
- FGFR3 alteration: Erdafitinib - HER2+: T-DXd - Pembrolizumab (if not used before) - EV (if not used before) - Platinum/Gemcitabine (if not used before)
Nivolumab + Cis/Gem
- FGFR3 alteration: Erdafitinib - HER2+: T-DXd - Pembrolizumab (if not used before) - EV (if not used before) - Platinum/Gemcitabine (if not used before)